Preterm Premature Rupture of Membranes
Conditions
Keywords
short term tocolysis, preterm premature rupture of membranes
Brief summary
Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.
Detailed description
The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence. The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM. Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation \<4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or \> 6 hours tocolysis at time of admission will be excluded. Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* English or Spanish speaking * preterm premature rupture of membranes * 26 - 32.6 weeks gestation * cervical dilation \</= 4 cm
Exclusion criteria
* suspected intrauterine or intraamniotic infection * \> 6 hours of tocolysis prior to admission * positive fetal lung maturity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hours of latency to delivery | 0 hours to > 168 hours | from start of study drug to delivery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| maternal postpartum length of stay | 0 hours to > 168 hours | from start of study drug to delivery |
| maternal infection rates | 0 hours to > 168 hours | from start of study drug to maternal discharge from hospital |
| neonatal ventilator days | 0 to 28 days | from delivery to 28 days of life |
| neonatal early onset infection | 0 to 28 days | from delivery to 28 days of life |
| neonatal length of stay | 0 to 28 days | from delivery to 28 days of life |
Countries
United States